Impact of vaccines on antimicrobial resistance

[Display omitted] •The inappropriate use and overuse of antibiotics accelerates antimicrobial resistance (AMR).•New antibiotic development has declined sharply in recent years.•A significant rise in deaths and medical costs from antibiotic-resistant bacterial infections could result by 2050.•Vaccine...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of infectious diseases Vol. 90; pp. 188 - 196
Main Authors:	Buchy, Philippe, Ascioglu, Sibel, Buisson, Yves, Datta, Sanjoy, Nissen, Michael, Tambyah, Paul Anantharajah, Vong, Sirenda
Format:	Journal Article
Language:	English
Published:	Canada Elsevier Ltd 01.01.2020 Elsevier
Subjects:	Animals Anti-Bacterial Agents - pharmacology Antibiotic Antimicrobial resistance Bacteria - drug effects Bacteria - genetics Bacteria - immunology Bacterial Infections - drug therapy Bacterial Infections - microbiology Bacterial Vaccines - genetics Bacterial Vaccines - immunology Drug Resistance, Bacterial Humans Inappropriate Prescribing Vaccine Antibiotic Vaccine Antimicrobial resistance
ISSN:	1201-9712, 1878-3511, 1878-3511
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	[Display omitted] •The inappropriate use and overuse of antibiotics accelerates antimicrobial resistance (AMR).•New antibiotic development has declined sharply in recent years.•A significant rise in deaths and medical costs from antibiotic-resistant bacterial infections could result by 2050.•Vaccines can prevent bacterial and viral infections from occurring and spreading.•Preventing infections and their transmission should reduce antibiotic use and AMR. Antibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has become a prolific global issue, due to significant increases in antibiotic use in humans, livestock and agriculture, inappropriate use (under-dosing and over-prescribing), and misuse of antibiotics (for viral infections where they are ineffective). Fewer new antibiotics are being developed. AMR is now considered a key threat to global health, leading to more mortality and increased healthcare costs threatening future conduct of routine medical procedures. Traditional approaches to address AMR include antibiotic stewardship, better hygiene/infection control, promoting antibiotic research and development, and restricting use for agricultural purposes. While antibiotic development is declining, vaccine technology is growing. This review shows how vaccines can decrease AMR by preventing bacterial and viral infections, thereby reducing the use/misuse of antibiotics, and by preventing antibiotic-resistant infections. Vaccines are less likely to induce resistance. Some future uses and developments of vaccines are also discussed. Vaccines, along with other approaches, can help reduce AMR by preventing (resistant) infections and reducing antibiotic use. Industry and governments must focus on the development of novel vaccines and drugs against resistant infections to successfully reduce AMR. A graphical abstract is available online.
AbstractList	Antibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has become a prolific global issue, due to significant increases in antibiotic use in humans, livestock and agriculture, inappropriate use (under-dosing and over-prescribing), and misuse of antibiotics (for viral infections where they are ineffective). Fewer new antibiotics are being developed.DRIVERS OF ANTIMICROBIAL RESISTANCEAntibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has become a prolific global issue, due to significant increases in antibiotic use in humans, livestock and agriculture, inappropriate use (under-dosing and over-prescribing), and misuse of antibiotics (for viral infections where they are ineffective). Fewer new antibiotics are being developed.AMR is now considered a key threat to global health, leading to more mortality and increased healthcare costs threatening future conduct of routine medical procedures. Traditional approaches to address AMR include antibiotic stewardship, better hygiene/infection control, promoting antibiotic research and development, and restricting use for agricultural purposes.THE PROBLEM OF AMRAMR is now considered a key threat to global health, leading to more mortality and increased healthcare costs threatening future conduct of routine medical procedures. Traditional approaches to address AMR include antibiotic stewardship, better hygiene/infection control, promoting antibiotic research and development, and restricting use for agricultural purposes.While antibiotic development is declining, vaccine technology is growing. This review shows how vaccines can decrease AMR by preventing bacterial and viral infections, thereby reducing the use/misuse of antibiotics, and by preventing antibiotic-resistant infections. Vaccines are less likely to induce resistance. Some future uses and developments of vaccines are also discussed.VACCINES AS A TOOL TO REDUCE AMRWhile antibiotic development is declining, vaccine technology is growing. This review shows how vaccines can decrease AMR by preventing bacterial and viral infections, thereby reducing the use/misuse of antibiotics, and by preventing antibiotic-resistant infections. Vaccines are less likely to induce resistance. Some future uses and developments of vaccines are also discussed.Vaccines, along with other approaches, can help reduce AMR by preventing (resistant) infections and reducing antibiotic use. Industry and governments must focus on the development of novel vaccines and drugs against resistant infections to successfully reduce AMR. A graphical abstract is available online.CONCLUSIONSVaccines, along with other approaches, can help reduce AMR by preventing (resistant) infections and reducing antibiotic use. Industry and governments must focus on the development of novel vaccines and drugs against resistant infections to successfully reduce AMR. A graphical abstract is available online. Drivers of antimicrobial resistance: Antibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has become a prolific global issue, due to significant increases in antibiotic use in humans, livestock and agriculture, inappropriate use (under-dosing and over-prescribing), and misuse of antibiotics (for viral infections where they are ineffective). Fewer new antibiotics are being developed. The problem of AMR: AMR is now considered a key threat to global health, leading to more mortality and increased healthcare costs threatening future conduct of routine medical procedures. Traditional approaches to address AMR include antibiotic stewardship, better hygiene/infection control, promoting antibiotic research and development, and restricting use for agricultural purposes. Vaccines as a tool to reduce AMR: While antibiotic development is declining, vaccine technology is growing. This review shows how vaccines can decrease AMR by preventing bacterial and viral infections, thereby reducing the use/misuse of antibiotics, and by preventing antibiotic-resistant infections. Vaccines are less likely to induce resistance. Some future uses and developments of vaccines are also discussed. Conclusions: Vaccines, along with other approaches, can help reduce AMR by preventing (resistant) infections and reducing antibiotic use. Industry and governments must focus on the development of novel vaccines and drugs against resistant infections to successfully reduce AMR. A graphical abstract is available online. Keywords: Antimicrobial resistance, Vaccine, Antibiotic Antibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has become a prolific global issue, due to significant increases in antibiotic use in humans, livestock and agriculture, inappropriate use (under-dosing and over-prescribing), and misuse of antibiotics (for viral infections where they are ineffective). Fewer new antibiotics are being developed. AMR is now considered a key threat to global health, leading to more mortality and increased healthcare costs threatening future conduct of routine medical procedures. Traditional approaches to address AMR include antibiotic stewardship, better hygiene/infection control, promoting antibiotic research and development, and restricting use for agricultural purposes. While antibiotic development is declining, vaccine technology is growing. This review shows how vaccines can decrease AMR by preventing bacterial and viral infections, thereby reducing the use/misuse of antibiotics, and by preventing antibiotic-resistant infections. Vaccines are less likely to induce resistance. Some future uses and developments of vaccines are also discussed. Vaccines, along with other approaches, can help reduce AMR by preventing (resistant) infections and reducing antibiotic use. Industry and governments must focus on the development of novel vaccines and drugs against resistant infections to successfully reduce AMR. A graphical abstract is available online. [Display omitted] •The inappropriate use and overuse of antibiotics accelerates antimicrobial resistance (AMR).•New antibiotic development has declined sharply in recent years.•A significant rise in deaths and medical costs from antibiotic-resistant bacterial infections could result by 2050.•Vaccines can prevent bacterial and viral infections from occurring and spreading.•Preventing infections and their transmission should reduce antibiotic use and AMR. Antibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has become a prolific global issue, due to significant increases in antibiotic use in humans, livestock and agriculture, inappropriate use (under-dosing and over-prescribing), and misuse of antibiotics (for viral infections where they are ineffective). Fewer new antibiotics are being developed. AMR is now considered a key threat to global health, leading to more mortality and increased healthcare costs threatening future conduct of routine medical procedures. Traditional approaches to address AMR include antibiotic stewardship, better hygiene/infection control, promoting antibiotic research and development, and restricting use for agricultural purposes. While antibiotic development is declining, vaccine technology is growing. This review shows how vaccines can decrease AMR by preventing bacterial and viral infections, thereby reducing the use/misuse of antibiotics, and by preventing antibiotic-resistant infections. Vaccines are less likely to induce resistance. Some future uses and developments of vaccines are also discussed. Vaccines, along with other approaches, can help reduce AMR by preventing (resistant) infections and reducing antibiotic use. Industry and governments must focus on the development of novel vaccines and drugs against resistant infections to successfully reduce AMR. A graphical abstract is available online.
Author	Vong, Sirenda Nissen, Michael Buisson, Yves Datta, Sanjoy Ascioglu, Sibel Buchy, Philippe Tambyah, Paul Anantharajah
Author_xml	– sequence: 1 givenname: Philippe orcidid: 0000-0003-1372-3008 surname: Buchy fullname: Buchy, Philippe email: philippe.x.buchy@gsk.com organization: GSK, 23 Rochester Park, Singapore 139234, Singapore – sequence: 2 givenname: Sibel surname: Ascioglu fullname: Ascioglu, Sibel email: sibel.x.ascioglu@gsk.com organization: GSK, 23 Rochester Park, Singapore 139234, Singapore – sequence: 3 givenname: Yves surname: Buisson fullname: Buisson, Yves email: yvesbuisson@hotmail.com organization: Académie Nationale de Médecine, 16 rue Bonaparte, 75006 Paris, France – sequence: 4 givenname: Sanjoy surname: Datta fullname: Datta, Sanjoy email: sanjoy.k.datta@gsk.com organization: GSK, 23 Rochester Park, Singapore 139234, Singapore – sequence: 5 givenname: Michael orcidid: 0000-0003-1686-3313 surname: Nissen fullname: Nissen, Michael email: michael.d.nissen@gsk.com organization: GSK, 23 Rochester Park, Singapore 139234, Singapore – sequence: 6 givenname: Paul Anantharajah surname: Tambyah fullname: Tambyah, Paul Anantharajah email: mdcpat@nus.edu.sg organization: National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore – sequence: 7 givenname: Sirenda surname: Vong fullname: Vong, Sirenda email: vongs@who.int organization: World Health Organization, Regional Office for South-East Asia (WHO SEARO), Metropolitan Hotel, Bangla Sahib Road, Connaught Place, New Delhi 110001, India
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31622674$$D View this record in MEDLINE/PubMed
BookMark	eNqFkUtv1TAUhC1URB_wB1igLNkk-JE4DmKDKh5XqsQG1ta59jE6IY-L7Vup_x6HW7rooqxsjecbSzOX7GxZF2TsteCN4EK_GxsayTeSi6EIDefdM3YhTG9q1QlxVu7lqR56Ic_ZZUoj57zV2rxg50poKXXfXrBmNx_A5WoN1S04Rwumal0qWDLN5OK6J5iqiIlShsXhS_Y8wJTw1f15xX58_vT9-mt98-3L7vrjTe06o3KtuQLcS9WFgGZogRvTasXD3gUnnegH33e-da5zoEB4iahx6L0HoyTXKqgrtjvl-hVGe4g0Q7yzK5D9K6zxp4WYyU1og2p5L4IHxU3rwZtBd22PndImCN3pkvX2lHWI6-8jpmxnSg6nCRZcj8lKVfgNbov1zb31uJ_RP3z8r69ikCdDqSaliOHBIrjdRrGj3Uax2yibVkYpkHkEOcqQaV1yBJqeRj-cUCxl3xJGmxxhGcJTRJdLG_Q0_v4R7iZayMH0C-_-B_8BoD25AA
CitedBy_id	crossref_primary_10_1093_jacamr_dlae061 crossref_primary_10_1016_j_imbio_2022_152221 crossref_primary_10_1016_j_vaccine_2020_11_077 crossref_primary_10_3390_antibiotics10050471 crossref_primary_10_1007_s00203_023_03800_9 crossref_primary_10_1016_j_ecoenv_2023_114734 crossref_primary_10_51847_5P5Jo37fEX crossref_primary_10_1080_07391102_2024_2316762 crossref_primary_10_1007_s13204_022_02735_9 crossref_primary_10_1007_s00044_024_03326_9 crossref_primary_10_1186_s12934_022_01936_9 crossref_primary_10_1016_j_micpath_2024_106971 crossref_primary_10_1093_jac_dkad034 crossref_primary_10_3389_fpubh_2021_635266 crossref_primary_10_1111_cxo_13125 crossref_primary_10_22207_JPAM_16_4_01 crossref_primary_10_3390_cryst12020179 crossref_primary_10_1016_j_bbapap_2022_140782 crossref_primary_10_1016_j_ejmech_2022_114490 crossref_primary_10_3390_vaccines12080852 crossref_primary_10_1016_j_infpip_2025_100461 crossref_primary_10_1186_s12889_025_22462_4 crossref_primary_10_3389_fphar_2022_838092 crossref_primary_10_1016_j_ijid_2024_107023 crossref_primary_10_1093_ofid_ofad098 crossref_primary_10_3390_vaccines9111232 crossref_primary_10_1002_chem_202003480 crossref_primary_10_1002_fsn3_4071 crossref_primary_10_1016_j_micres_2020_126551 crossref_primary_10_1016_j_scitotenv_2023_163518 crossref_primary_10_3390_antibiotics13060565 crossref_primary_10_3390_life11060528 crossref_primary_10_22207_JPAM_18_1_42 crossref_primary_10_3389_fmicb_2023_1270018 crossref_primary_10_1080_03007995_2023_2200123 crossref_primary_10_1080_14760584_2022_2143349 crossref_primary_10_1016_j_ijbiomac_2024_136827 crossref_primary_10_1002_anbr_202200130 crossref_primary_10_1016_j_mtbio_2025_102266 crossref_primary_10_1016_j_vaccine_2022_04_050 crossref_primary_10_1093_jacamr_dlad062 crossref_primary_10_3390_antibiotics12010149 crossref_primary_10_1039_D5RA03414K crossref_primary_10_1097_HM9_0000000000000046 crossref_primary_10_15789_2220_7619_PFT_17901 crossref_primary_10_1038_s41598_025_02861_8 crossref_primary_10_3390_ph16070920 crossref_primary_10_3390_vaccines13090893 crossref_primary_10_1016_j_jddst_2021_102821 crossref_primary_10_1080_21645515_2024_2414551 crossref_primary_10_1590_1519_6984_285605 crossref_primary_10_1080_14760584_2021_1945450 crossref_primary_10_3390_vaccines9090988 crossref_primary_10_7717_peerj_11596 crossref_primary_10_1080_14760584_2023_2256394 crossref_primary_10_1186_s12879_025_11080_5 crossref_primary_10_1093_ofid_ofac420 crossref_primary_10_3390_ph15080942 crossref_primary_10_1080_14740338_2022_2106368 crossref_primary_10_1080_07391102_2021_1942211 crossref_primary_10_1186_s12992_024_01046_8 crossref_primary_10_1016_j_scitotenv_2023_168193 crossref_primary_10_3390_life14020246 crossref_primary_10_1002_SMMD_20230012 crossref_primary_10_1016_j_ijbiomac_2024_134977 crossref_primary_10_2147_IDR_S290835 crossref_primary_10_1080_21645515_2023_2215149 crossref_primary_10_1002_smsc_202400412 crossref_primary_10_3390_antibiotics11020142 crossref_primary_10_1080_21645515_2022_2151291 crossref_primary_10_7554_eLife_95328 crossref_primary_10_1111_nuf_12803 crossref_primary_10_3390_antibiotics12091429 crossref_primary_10_1016_j_sjbs_2021_08_054 crossref_primary_10_7759_cureus_65840 crossref_primary_10_1016_j_vaccine_2021_02_063 crossref_primary_10_1093_cid_ciae138 crossref_primary_10_1007_s10989_021_10245_5 crossref_primary_10_3390_vaccines10122100 crossref_primary_10_1007_s00103_019_03073_y crossref_primary_10_3390_vaccines10091505 crossref_primary_10_7554_eLife_85302 crossref_primary_10_1016_j_vaccine_2022_04_024 crossref_primary_10_1111_tmi_13865 crossref_primary_10_3390_ejihpe11040104 crossref_primary_10_1038_s41598_022_26859_8 crossref_primary_10_3390_vaccines13030245 crossref_primary_10_2174_1381612829666230130144731 crossref_primary_10_7554_eLife_95328_3 crossref_primary_10_3390_antibiotics12020274 crossref_primary_10_3390_antibiotics11020165 crossref_primary_10_1007_s12602_025_10705_0 crossref_primary_10_3390_antibiotics11020200 crossref_primary_10_1038_s41541_021_00351_2 crossref_primary_10_1016_j_banm_2023_12_010 crossref_primary_10_1080_21645515_2023_2300848 crossref_primary_10_1016_j_ijid_2021_09_045 crossref_primary_10_3390_bios12040188 crossref_primary_10_3390_ani10091717
Cites_doi	10.1186/s13073-016-0294-z 10.1371/journal.pone.0138941 10.1186/s13756-018-0336-y 10.1371/journal.pone.0203143 10.1186/s13567-018-0560-8 10.3201/eid2111.140780 10.1093/clinids/12.4.708 10.1056/NEJMoa051642 10.1080/07853890.2017.1407035 10.1073/pnas.1717160115 10.1080/21645515.2016.1259780 10.3201/eid2306.161331 10.1093/jac/dkf810 10.1159/000443360 10.1128/AAC.00830-12 10.1016/S2214-109X(17)30364-9 10.1128/AAC.34.11.2075 10.1128/AAC.48.6.2206-2213.2004 10.1016/j.jaci.2018.05.007 10.1542/peds.2007-0619 10.1073/pnas.1907833116 10.1086/648593 10.1038/nm.4465 10.1128/mBio.00428-16 10.1016/j.ajpath.2014.08.030 10.1007/s40273-015-0335-2 10.1016/S1473-3099(18)30605-4 10.1098/rstb.2013.0433 10.1371/journal.pone.0050688 10.1136/bmj.j2423 10.1086/605087 10.1017/S0950268804003565 10.3201/eid0402.980210 10.1371/journal.pone.0170550 10.1056/NEJMsb1609216 10.1128/AAC.49.6.2561-2564.2005 10.1038/d41586-017-08323-0 10.1038/ja.2017.124 10.1038/nm1145 10.1093/infdis/jir755 10.1016/j.cmi.2019.06.030 10.3389/fimmu.2018.01068 10.1073/pnas.1717161115 10.1097/INF.0000000000001814 10.1098/rstb.2014.0342 10.1371/journal.pmed.1001657 10.1016/j.vaccine.2010.03.030 10.1093/cid/ciw067 10.1371/journal.pmed.1001974 10.1097/INF.0000000000002160 10.1073/pnas.1717157115 10.1097/00006454-200301000-00006 10.1056/NEJM200001273420401 10.1086/648678 10.1111/irv.12398 10.1016/S1473-3099(18)30350-5 10.1128/JCM.01778-16 10.1371/journal.pone.0120290 10.1080/21645515.2015.1116654
ContentType	Journal Article
Copyright	2019 GlaxoSmithKline Biologicals S.A. Copyright © 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.
Copyright_xml	– notice: 2019 GlaxoSmithKline Biologicals S.A. – notice: Copyright © 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA
DOI	10.1016/j.ijid.2019.10.005
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Public Health
EISSN	1878-3511
EndPage	196
ExternalDocumentID	oai_doaj_org_article_f34071fda3084dad896547e5368f1656 31622674 10_1016_j_ijid_2019_10_005 S1201971219303972
Genre	Journal Article Review
GrantInformation_xml	– fundername: World Health Organization grantid: 001
GroupedDBID	--- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R ~HD 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW NCXOZ RIG 9DU AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c583t-603aeb235ffe894a0884630fbcfc2c179d75d4cc5ca3a1d2ee6e97dda832063f3
IEDL.DBID	DOA
ISICitedReferencesCount	116
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000502803300029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1201-9712 1878-3511
IngestDate	Fri Oct 03 12:46:03 EDT 2025 Wed Oct 01 15:11:02 EDT 2025 Mon Jul 21 05:42:54 EDT 2025 Sat Nov 29 07:05:25 EST 2025 Tue Nov 18 22:32:31 EST 2025 Fri Feb 23 02:49:21 EST 2024 Tue Oct 14 19:35:15 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Keywords	Antibiotic Vaccine Antimicrobial resistance
Language	English
License	This is an open access article under the CC BY-NC-ND license. Copyright © 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c583t-603aeb235ffe894a0884630fbcfc2c179d75d4cc5ca3a1d2ee6e97dda832063f3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ORCID	0000-0003-1372-3008 0000-0003-1686-3313
OpenAccessLink	https://doaj.org/article/f34071fda3084dad896547e5368f1656
PMID	31622674
PQID	2307130844
PQPubID	23479
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_f34071fda3084dad896547e5368f1656 proquest_miscellaneous_2307130844 pubmed_primary_31622674 crossref_primary_10_1016_j_ijid_2019_10_005 crossref_citationtrail_10_1016_j_ijid_2019_10_005 elsevier_sciencedirect_doi_10_1016_j_ijid_2019_10_005 elsevier_clinicalkey_doi_10_1016_j_ijid_2019_10_005
PublicationCentury	2000
PublicationDate	January 2020 2020-01-00 2020-Jan 20200101 2020-01-01
PublicationDateYYYYMMDD	2020-01-01
PublicationDate_xml	– month: 01 year: 2020 text: January 2020
PublicationDecade	2020
PublicationPlace	Canada
PublicationPlace_xml	– name: Canada
PublicationTitle	International journal of infectious diseases
PublicationTitleAlternate	Int J Infect Dis
PublicationYear	2020
Publisher	Elsevier Ltd Elsevier
Publisher_xml	– name: Elsevier Ltd – name: Elsevier
References	Fireman, Black, Shinefield, Lee, Lewis, Ray (bib0070) 2003; 22 Jorgensen, Doern, Maher, Howell, Redding (bib0160) 1990; 34 Fu, Wang, Tian, Kang, Zeng (bib0080) 2019; 38 Heilmann, Rice, Miller, Miller, Beekmann, Pfaller (bib0120) 2005; 49 World Health Organization (WHO) (bib0385) 2008 Gherardi, D’Ambrosio, Visaggio, Dicuonzo, Del Grosso, Pantosti (bib0095) 2012; 56 Temime, Guillemot, Boelle (bib0325) 2004; 48 Zhou, Shefer, Kong, Nuorti (bib0425) 2008; 121 Baker, Payne, Rappuoli, De Gregorio (bib0015) 2018; 115 Kyaw, Lynfield, Schaffner, Craig, Hadler, Reingold (bib0195) 2006; 354 Rappuoli, Bloom, Black (bib0285) 2017; 552 Bisgard, Kao, Leake, Strebel, Perkins, Wharton (bib0020) 1998; 4 Jansen, Knirsch, Anderson (bib0145) 2018; 24 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (bib0140) 2015 Hegerle, Choi, Sinclair, Amin, Ollivault-Shiflett, Curtis (bib0115) 2018; 13 UK Government (bib0355) 2019 GAVI Vaccine Alliance (bib0085) 2007 Van Effelterre, Moore, Fierens, Whitney, White, Pelton (bib0370) 2010; 28 Chen, He (bib0050) 2017; 13 Jokinen, Rinta-Kokko, Siira, Palmu, Virtanen, Nohynek (bib0155) 2015; 10 Yang, Yao, Ma, Shi, Yuan, Yang (bib0420) 2015; 10 National Institute for Health and Care Excellence (NICE) (bib0245) 2013 Tagliabue, Rappuoli (bib0315) 2018; 9 World Health Organization (WHO) (bib0395) 2017 Neuzil, Mellen, Wright, Mitchel, Griffin (bib0255) 2000; 342 Vaccines Europe (bib0365) 2016 Lange, Buerger, Stallmach, Bruns (bib0205) 2016; 34 Cassini, Hogberg, Plachouras, Quattrocchi, Hoxha, Simonsen (bib0035) 2019; 19 Francino (bib0075) 2015; 6 World Health Organization (WHO) (bib0405) 2019 Kash, Taubenberger (bib0165) 2015; 185 Tomczyk, Lynfield, Schaffner, Reingold, Miller, Petit (bib0345) 2016; 62 Ventola (bib0375) 2015; 40 Knol, Wagenvoort, Sanders, Elberse, Vlaminckx, de Melker (bib0185) 2015; 21 Kayal, Degand (bib0170) 2010; 16 World Health Organization (WHO) (bib0410) 2019 Peltola, Rod, Jonsdottir, Bottiger, Coolidge (bib0270) 1990; 12 Tekle, Nielsen, Liu, Pettigrew, Meyers, Galvani (bib0320) 2012; 7 Langdon, Crook, Dantas (bib0200) 2016; 8 Pilishvili, Lexau, Farley, Hadler, Harrison, Bennett (bib0275) 2010; 201 Simpkin, Renwick, Kelly, Mossialos (bib0305) 2017; 70 Ginsburg, Klugman (bib0100) 2017; 5 Greenwood (bib0105) 2014; 369 Klein, Monteforte, Gupta, Jiang, May, Hsieh (bib0180) 2016; 10 Buckley, Henschke, Bergman, Skidmore, Klemm, Villanueva (bib0030) 2019; 25 Interagency Coordination Group (IACG) on Antimicrobial Resistance. No time to wait: securing the future from drug-resistant infections. Report to the Secretary General of the United Nations; April 2019. Available from The Immunisation Advisory Centre (bib0335) 2017 World Organisation for Animal Health (OIE) (bib0415) 2016 Bloom, Black, Salisbury, Rappuoli (bib0025) 2018; 115 Cohen, Biscardi, Levy (bib0055) 2016; 12 Naylor, Atun, Zhu, Kulasabanathan, Silva, Chatterjee (bib0250) 2018; 7 Ultsch, Damm, Beutels, Bilcke, Bruggenjurgen, Gerber-Grote (bib0360) 2016; 34 Nair, Venkitanarayanan, Kollanoor Johny (bib0240) 2018; 7 Temime, Boelle, Valleron, Guillemot (bib0330) 2005; 133 Feldman, Mayer Bridwell, Scott, Vinogradov, McKee, Chavez (bib0065) 2019; 116 Andam, Worby, Gierke, McGee, Pilishvili, Hanage (bib0005) 2017; 23 O’Neill (bib0260) 2016 Centers for Disease Control and Prevention (CDC) (bib0040) 2013 The World Bank (bib0340) 2017 Public Health Agency of Canada (bib0280) 2017 Department of Health and Social Care (bib0060) 2018 Levy, Marshall (bib0215) 2004; 10 Sherman, Anderson, Dal Pan, Gray, Gross, Hunter (bib0300) 2016; 375 Kwong, Maaten, Upshur, Patrick, Marra (bib0190) 2009; 49 Centers for Disease Control and Prevention (CDC) (bib0045) 2017 Schmid, Rauber, Betsch, Lidolt, Denker (bib0290) 2017; 12 Hoelzer, Bielke, Blake, Cox, Cutting, Devriendt (bib0130) 2018; 49 Sevilla, Bloom, Cadarette, Jit, Lipsitch (bib0295) 2018; 115 Vetter, Denizer, Friedland, Krishnan, Shapiro (bib0380) 2018; 50 Hampton, Farley, Schaffner, Thomas, Reingold, Harrison (bib0110) 2012; 205 [Accessed 14 May 2019]. Kennedy, Read (bib0175) 2017; 284 Lipsitch, Siber (bib0220) 2016; 7 Hoban, Felmingham (bib0125) 2002; 50 Mitchell, Lipsitch, Hanage (bib0235) 2015; 370 Olarte, Kaplan, Barson, Romero, Lin, Tan (bib0265) 2017; 55 Sumpradit, Wongkongkathep, Poonpolsup, Janejai, Paveenkittiporn, Boonyarit (bib0310) 2017; 358 Andrews, Baker, Marks, Alsan, Garrett, Gellin (bib0010) 2019; 19 Johansson, Kalin, Tiveljung-Lindell, Giske, Hedlund (bib0150) 2010; 50 Mallory, Lindesmith, Baric (bib0230) 2018; 142 World Health Organization (WHO) (bib0390) 2015 Laxminarayan, Chaudhury (bib0210) 2016; 13 Liu, Wang, Zhang, Li, Luan, Li (bib0225) 2018; 37 World Health Organization (WHO) (bib0400) 2018 GAVI Vaccine Alliance (bib0090) 2019 Tregnaghi, Saez-Llorens, Lopez, Abate, Smith, Posleman (bib0350) 2014; 11 Liu (10.1016/j.ijid.2019.10.005_bib0225) 2018; 37 Schmid (10.1016/j.ijid.2019.10.005_bib0290) 2017; 12 Tregnaghi (10.1016/j.ijid.2019.10.005_bib0350) 2014; 11 Bloom (10.1016/j.ijid.2019.10.005_bib0025) 2018; 115 Fu (10.1016/j.ijid.2019.10.005_bib0080) 2019; 38 World Health Organization (WHO) (10.1016/j.ijid.2019.10.005_bib0400) 2018 World Health Organization (WHO) (10.1016/j.ijid.2019.10.005_bib0410) 2019 The Immunisation Advisory Centre (10.1016/j.ijid.2019.10.005_bib0335) 2017 Neuzil (10.1016/j.ijid.2019.10.005_bib0255) 2000; 342 World Organisation for Animal Health (OIE) (10.1016/j.ijid.2019.10.005_bib0415) 2016 Andam (10.1016/j.ijid.2019.10.005_bib0005) 2017; 23 Bisgard (10.1016/j.ijid.2019.10.005_bib0020) 1998; 4 Hampton (10.1016/j.ijid.2019.10.005_bib0110) 2012; 205 UK Government (10.1016/j.ijid.2019.10.005_bib0355) 2019 Lipsitch (10.1016/j.ijid.2019.10.005_bib0220) 2016; 7 Baker (10.1016/j.ijid.2019.10.005_bib0015) 2018; 115 National Institute for Health and Care Excellence (NICE) (10.1016/j.ijid.2019.10.005_bib0245) 2013 Vetter (10.1016/j.ijid.2019.10.005_bib0380) 2018; 50 Ginsburg (10.1016/j.ijid.2019.10.005_bib0100) 2017; 5 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (10.1016/j.ijid.2019.10.005_bib0140) 2015 Naylor (10.1016/j.ijid.2019.10.005_bib0250) 2018; 7 Tagliabue (10.1016/j.ijid.2019.10.005_bib0315) 2018; 9 GAVI Vaccine Alliance (10.1016/j.ijid.2019.10.005_bib0090) 2019 Heilmann (10.1016/j.ijid.2019.10.005_bib0120) 2005; 49 Johansson (10.1016/j.ijid.2019.10.005_bib0150) 2010; 50 O’Neill (10.1016/j.ijid.2019.10.005_bib0260) 2016 Simpkin (10.1016/j.ijid.2019.10.005_bib0305) 2017; 70 Ventola (10.1016/j.ijid.2019.10.005_bib0375) 2015; 40 Klein (10.1016/j.ijid.2019.10.005_bib0180) 2016; 10 Department of Health and Social Care (10.1016/j.ijid.2019.10.005_bib0060) 2018 Kennedy (10.1016/j.ijid.2019.10.005_bib0175) 2017; 284 Kayal (10.1016/j.ijid.2019.10.005_bib0170) 2010; 16 Mallory (10.1016/j.ijid.2019.10.005_bib0230) 2018; 142 Pilishvili (10.1016/j.ijid.2019.10.005_bib0275) 2010; 201 Sumpradit (10.1016/j.ijid.2019.10.005_bib0310) 2017; 358 World Health Organization (WHO) (10.1016/j.ijid.2019.10.005_bib0395) 2017 Tekle (10.1016/j.ijid.2019.10.005_bib0320) 2012; 7 Tomczyk (10.1016/j.ijid.2019.10.005_bib0345) 2016; 62 Nair (10.1016/j.ijid.2019.10.005_bib0240) 2018; 7 Lange (10.1016/j.ijid.2019.10.005_bib0205) 2016; 34 GAVI Vaccine Alliance (10.1016/j.ijid.2019.10.005_bib0085) 2007 Levy (10.1016/j.ijid.2019.10.005_bib0215) 2004; 10 Public Health Agency of Canada (10.1016/j.ijid.2019.10.005_bib0280) 2017 World Health Organization (WHO) (10.1016/j.ijid.2019.10.005_bib0405) 2019 Francino (10.1016/j.ijid.2019.10.005_bib0075) 2015; 6 Laxminarayan (10.1016/j.ijid.2019.10.005_bib0210) 2016; 13 Rappuoli (10.1016/j.ijid.2019.10.005_bib0285) 2017; 552 Kyaw (10.1016/j.ijid.2019.10.005_bib0195) 2006; 354 Zhou (10.1016/j.ijid.2019.10.005_bib0425) 2008; 121 Cassini (10.1016/j.ijid.2019.10.005_bib0035) 2019; 19 Fireman (10.1016/j.ijid.2019.10.005_bib0070) 2003; 22 Sherman (10.1016/j.ijid.2019.10.005_bib0300) 2016; 375 Greenwood (10.1016/j.ijid.2019.10.005_bib0105) 2014; 369 Langdon (10.1016/j.ijid.2019.10.005_bib0200) 2016; 8 Kwong (10.1016/j.ijid.2019.10.005_bib0190) 2009; 49 Sevilla (10.1016/j.ijid.2019.10.005_bib0295) 2018; 115 Yang (10.1016/j.ijid.2019.10.005_bib0420) 2015; 10 Centers for Disease Control and Prevention (CDC) (10.1016/j.ijid.2019.10.005_bib0040) 2013 Gherardi (10.1016/j.ijid.2019.10.005_bib0095) 2012; 56 Knol (10.1016/j.ijid.2019.10.005_bib0185) 2015; 21 World Health Organization (WHO) (10.1016/j.ijid.2019.10.005_bib0385) 2008 Jokinen (10.1016/j.ijid.2019.10.005_bib0155) 2015; 10 Cohen (10.1016/j.ijid.2019.10.005_bib0055) 2016; 12 Van Effelterre (10.1016/j.ijid.2019.10.005_bib0370) 2010; 28 Jorgensen (10.1016/j.ijid.2019.10.005_bib0160) 1990; 34 Andrews (10.1016/j.ijid.2019.10.005_bib0010) 2019; 19 Jansen (10.1016/j.ijid.2019.10.005_bib0145) 2018; 24 Temime (10.1016/j.ijid.2019.10.005_bib0325) 2004; 48 Hoelzer (10.1016/j.ijid.2019.10.005_bib0130) 2018; 49 Mitchell (10.1016/j.ijid.2019.10.005_bib0235) 2015; 370 Centers for Disease Control and Prevention (CDC) (10.1016/j.ijid.2019.10.005_bib0045) 2017 Olarte (10.1016/j.ijid.2019.10.005_bib0265) 2017; 55 Buckley (10.1016/j.ijid.2019.10.005_bib0030) 2019; 25 Feldman (10.1016/j.ijid.2019.10.005_bib0065) 2019; 116 World Health Organization (WHO) (10.1016/j.ijid.2019.10.005_bib0390) 2015 The World Bank (10.1016/j.ijid.2019.10.005_bib0340) 2017 Hegerle (10.1016/j.ijid.2019.10.005_bib0115) 2018; 13 Ultsch (10.1016/j.ijid.2019.10.005_bib0360) 2016; 34 Hoban (10.1016/j.ijid.2019.10.005_bib0125) 2002; 50 10.1016/j.ijid.2019.10.005_bib0135 Peltola (10.1016/j.ijid.2019.10.005_bib0270) 1990; 12 Chen (10.1016/j.ijid.2019.10.005_bib0050) 2017; 13 Temime (10.1016/j.ijid.2019.10.005_bib0330) 2005; 133 Kash (10.1016/j.ijid.2019.10.005_bib0165) 2015; 185 Vaccines Europe (10.1016/j.ijid.2019.10.005_bib0365) 2016
References_xml	– volume: 37 start-page: e145 year: 2018 end-page: e148 ident: bib0225 article-title: Pertussis outbreak in a primary school in China: infection and transmission of the macrolide-resistant publication-title: Pediatr Infect Dis J – year: 2013 ident: bib0245 article-title: Guide to the methods of technology appraisal 2013 – volume: 342 start-page: 225 year: 2000 end-page: 231 ident: bib0255 article-title: The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children publication-title: N Engl J Med – volume: 40 start-page: 277 year: 2015 end-page: 283 ident: bib0375 article-title: The antibiotic resistance crisis: part 1: causes and threats publication-title: Pharm Ther – volume: 375 start-page: 2293 year: 2016 end-page: 2297 ident: bib0300 article-title: Real-world evidence — what is it and what can it tell us? publication-title: N Engl J Med – year: 2015 ident: bib0140 article-title: The pharmaceutical industry and global health – volume: 21 start-page: 2040 year: 2015 end-page: 2044 ident: bib0185 article-title: Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands publication-title: Emerg Infect Dis – volume: 201 start-page: 32 year: 2010 end-page: 41 ident: bib0275 article-title: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine publication-title: J Infect Dis – year: 2017 ident: bib0395 article-title: WHO publishes list of bacteria for which new antibiotics are urgently needed – volume: 115 start-page: 12911 year: 2018 end-page: 12919 ident: bib0295 article-title: Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR publication-title: Proc Natl Acad Sci USA – volume: 34 start-page: 260 year: 2016 end-page: 268 ident: bib0205 article-title: Effects of antibiotics on gut microbiota publication-title: Dig Dis – volume: 11 year: 2014 ident: bib0350 article-title: Efficacy of pneumococcal nontypable publication-title: PLoS Med – volume: 369 year: 2014 ident: bib0105 article-title: The contribution of vaccination to global health: past, present and future publication-title: Philos Trans R Soc Lond B Biol Sci – year: 2018 ident: bib0400 article-title: Draft thirteenth general programme of work, 2019–2023 – year: 2013 ident: bib0040 article-title: Antibiotic resistance threats in the United States, 2013 – volume: 205 start-page: 401 year: 2012 end-page: 411 ident: bib0110 article-title: Prevention of antibiotic-nonsusceptible publication-title: J Infect Dis – volume: 13 start-page: 744 year: 2017 end-page: 756 ident: bib0050 article-title: Immune persistence after pertussis vaccination publication-title: Hum Vaccin Immunother – volume: 142 start-page: 64 year: 2018 end-page: 66 ident: bib0230 article-title: Vaccination-induced herd immunity: successes and challenges publication-title: J Allergy Clin Immunol – volume: 133 start-page: 493 year: 2005 end-page: 501 ident: bib0330 article-title: Penicillin-resistant pneumococcal meningitis: high antibiotic exposure impedes new vaccine protection publication-title: Epidemiol Infect – year: 2018 ident: bib0060 article-title: DHSC joins global fight to tackle antimicrobial resistance in animals – volume: 38 start-page: 370 year: 2019 end-page: 376 ident: bib0080 article-title: infection in infants and young children in Shanghai, China, 2016-2017: clinical features, genotype variations of antigenic genes and macrolides resistance publication-title: Pediatr Infect Dis J – volume: 34 start-page: 2075 year: 1990 end-page: 2080 ident: bib0160 article-title: Antimicrobial resistance among respiratory isolates publication-title: Antimicrob Agents Chemother – volume: 10 year: 2015 ident: bib0420 article-title: Variation in publication-title: PLoS One – volume: 4 start-page: 229 year: 1998 end-page: 237 ident: bib0020 article-title: invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease publication-title: Emerg Infect Dis – volume: 7 year: 2016 ident: bib0220 article-title: How can vaccines contribute to solving the antimicrobial resistance problem? publication-title: mBio – volume: 70 start-page: 1087 year: 2017 end-page: 1096 ident: bib0305 article-title: Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps publication-title: J Antibiot – volume: 552 start-page: 165 year: 2017 end-page: 167 ident: bib0285 article-title: Deploy vaccines to fight superbugs publication-title: Nature – year: 2019 ident: bib0355 article-title: Tackling antimicrobial resistance 2019–2024. The UK’s five-year national action plan – year: 2015 ident: bib0390 article-title: Pneumococcal disease – volume: 7 start-page: 58 year: 2018 ident: bib0250 article-title: Estimating the burden of antimicrobial resistance: a systematic literature review publication-title: Antimicrob Resist Infect Control – year: 2016 ident: bib0415 article-title: The OIE strategy on antimicrobial resistance and the prudent use of antimicrobials – volume: 7 year: 2018 ident: bib0240 article-title: Antibiotic-resistant salmonella in the food supply and the potential role of antibiotic alternatives for control publication-title: Foods (Basel, Switzerland) – reference: Interagency Coordination Group (IACG) on Antimicrobial Resistance. No time to wait: securing the future from drug-resistant infections. Report to the Secretary General of the United Nations; April 2019. Available from: – volume: 25 start-page: 1213 year: 2019 end-page: 1225 ident: bib0030 article-title: Impact of vaccination on antibiotic usage: a systematic review and meta-analysis publication-title: Clin Microbiol Infect – volume: 185 start-page: 1528 year: 2015 end-page: 1536 ident: bib0165 article-title: The role of viral, host, and secondary bacterial factors in influenza pathogenesis publication-title: Am J Pathol – volume: 8 start-page: 39 year: 2016 ident: bib0200 article-title: The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation publication-title: Genome Med – volume: 9 start-page: 1068 year: 2018 ident: bib0315 article-title: Changing priorities in vaccinology: antibiotic resistance moving to the top publication-title: Front Immunol – volume: 19 start-page: 56 year: 2019 end-page: 66 ident: bib0035 article-title: Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis publication-title: Lancet Infect Dis – volume: 13 year: 2018 ident: bib0115 article-title: Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with publication-title: PLoS One – year: 2007 ident: bib0085 article-title: GAVI Alliance announces dramatic funding boost for Hib vaccine – volume: 13 year: 2016 ident: bib0210 article-title: Antibiotic resistance in India: drivers and opportunities for action publication-title: PLoS Med – year: 2008 ident: bib0385 article-title: WHO guide for standardization of economic evaluations of immunization programmes – year: 2016 ident: bib0365 article-title: Policy paper on: the role of vaccination in reducing antimicrobial resistance (AMR) – volume: 6 start-page: 1543 year: 2015 ident: bib0075 article-title: Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances publication-title: Front Microbiol – reference: . [Accessed 14 May 2019]. – volume: 284 start-page: 1 year: 2017 end-page: 9 ident: bib0175 article-title: Why does drug resistance readily evolve but vaccine resistance does not? publication-title: Proc Biol Sci – year: 2017 ident: bib0340 article-title: Drug-resistant infections: a threat to our economic future – volume: 10 year: 2015 ident: bib0155 article-title: Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children—a population-based study publication-title: PLoS One – volume: 10 start-page: S122 year: 2004 end-page: S129 ident: bib0215 article-title: Antibacterial resistance worldwide: causes, challenges and responses publication-title: Nat Med – volume: 22 start-page: 10 year: 2003 end-page: 16 ident: bib0070 article-title: Impact of the pneumococcal conjugate vaccine on otitis media publication-title: Pediatr Infect Dis J – volume: 354 start-page: 1455 year: 2006 end-page: 1463 ident: bib0195 article-title: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant publication-title: N Engl J Med – volume: 115 start-page: 12887 year: 2018 end-page: 12895 ident: bib0015 article-title: Technologies to address antimicrobial resistance publication-title: Proc Natl Acad Sci USA – volume: 12 start-page: 277 year: 2016 end-page: 284 ident: bib0055 article-title: The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014 publication-title: Hum Vaccin Immunother – volume: 49 start-page: 750 year: 2009 end-page: 756 ident: bib0190 article-title: The effect of universal influenza immunization on antibiotic prescriptions: an ecological study publication-title: Clin Infect Dis – volume: 12 start-page: 708 year: 1990 end-page: 715 ident: bib0270 article-title: Life-threatening publication-title: Rev Infect Dis – volume: 121 start-page: 253 year: 2008 end-page: 260 ident: bib0425 article-title: Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004 publication-title: Pediatrics – volume: 16 start-page: 133 year: 2010 end-page: 142 ident: bib0170 article-title: Après 20 ans de vaccination efficace, que reste-t-il des infections à publication-title: Med Ther – volume: 28 start-page: 3650 year: 2010 end-page: 3660 ident: bib0370 article-title: A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination publication-title: Vaccine – volume: 19 start-page: e26 year: 2019 end-page: e30 ident: bib0010 article-title: Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance publication-title: Lancet Infect Dis – volume: 62 start-page: 1119 year: 2016 end-page: 1125 ident: bib0345 article-title: Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine publication-title: Clin Infect Dis – year: 2016 ident: bib0260 article-title: Review on antimicrobial resistance — tackling drug-resistant infections globally: final report and recommendations – volume: 358 start-page: j3415 year: 2017 ident: bib0310 article-title: New chapter in tackling antimicrobial resistance in Thailand publication-title: BMJ – year: 2019 ident: bib0405 article-title: Pneumococcal conjugate vaccines – volume: 49 start-page: 64 year: 2018 ident: bib0130 article-title: Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs publication-title: Vet Res – volume: 24 start-page: 10 year: 2018 end-page: 19 ident: bib0145 article-title: The role of vaccines in preventing bacterial antimicrobial resistance publication-title: Nat Med – year: 2017 ident: bib0045 article-title: Pneumococcal vaccination — in Depth – volume: 34 start-page: 227 year: 2016 end-page: 244 ident: bib0360 article-title: Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European Vaccine Economics Community publication-title: PharmacoEcon – volume: 10 start-page: 394 year: 2016 end-page: 403 ident: bib0180 article-title: The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis publication-title: Influenza Other Respir Viruses – volume: 50 start-page: 110 year: 2018 end-page: 120 ident: bib0380 article-title: Understanding modern-day vaccines: what you need to know publication-title: Ann Med – volume: 115 start-page: 12868 year: 2018 end-page: 12871 ident: bib0025 article-title: Antimicrobial resistance and the role of vaccines publication-title: Proc Natl Acad Sci USA – year: 2017 ident: bib0280 article-title: Vaccine preventable disease — surveillance report to December 31, 2015 – volume: 56 start-page: 4965 year: 2012 end-page: 4968 ident: bib0095 article-title: Serotype and clonal evolution of penicillin-nonsusceptible invasive publication-title: Antimicrob Agents Chemother – volume: 23 start-page: 1012 year: 2017 end-page: 1015 ident: bib0005 article-title: Penicillin resistance of nonvaccine type pneumococcus before and after PCV13 introduction, United States publication-title: Emerg Infect Dis – year: 2019 ident: bib0410 article-title: Ten threats to global health in 2019 – volume: 116 start-page: 18655 year: 2019 end-page: 18663 ident: bib0065 article-title: A promising bioconjugate vaccine against hypervirulent publication-title: Proc Natl Acad Sci USA – volume: 50 start-page: 202 year: 2010 end-page: 209 ident: bib0150 article-title: Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods publication-title: Clin Infect Dis – volume: 49 start-page: 2561 year: 2005 end-page: 2564 ident: bib0120 article-title: Decreasing prevalence of beta-lactamase production among respiratory tract isolates of publication-title: Antimicrob Agents Chemother – year: 2019 ident: bib0090 article-title: type b vaccine support – volume: 5 start-page: e1176 year: 2017 end-page: e1177 ident: bib0100 article-title: Vaccination to reduce antimicrobial resistance publication-title: Lancet Glob Health – volume: 370 year: 2015 ident: bib0235 article-title: Carriage burden, multiple colonization and antibiotic pressure promote emergence of resistant vaccine escape pneumococci publication-title: Philos Trans R Soc Lond B Biol Sci – volume: 7 year: 2012 ident: bib0320 article-title: Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains publication-title: PLoS One – volume: 12 year: 2017 ident: bib0290 article-title: Barriers of influenza vaccination intention and behavior — a systematic review of influenza vaccine hesitancy, 2005–2016 publication-title: PLoS One – year: 2017 ident: bib0335 article-title: A brief history of vaccination – volume: 48 start-page: 2206 year: 2004 end-page: 2213 ident: bib0325 article-title: Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance publication-title: Antimicrob Agents Chemother – volume: 55 start-page: 724 year: 2017 end-page: 734 ident: bib0265 article-title: Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States publication-title: J Clin Microbiol – volume: 50 start-page: 49 year: 2002 end-page: 59 ident: bib0125 article-title: The PROTEKT surveillance study: antimicrobial susceptibility of publication-title: J Antimicrob Chemother – volume: 8 start-page: 39 issue: 1 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0200 article-title: The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation publication-title: Genome Med doi: 10.1186/s13073-016-0294-z – year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0060 – volume: 10 issue: 9 year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0420 article-title: Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970–2014) publication-title: PLoS One doi: 10.1371/journal.pone.0138941 – year: 2007 ident: 10.1016/j.ijid.2019.10.005_bib0085 – year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0140 – volume: 7 start-page: 58 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0250 article-title: Estimating the burden of antimicrobial resistance: a systematic literature review publication-title: Antimicrob Resist Infect Control doi: 10.1186/s13756-018-0336-y – year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0340 – volume: 13 issue: 9 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0115 article-title: Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa publication-title: PLoS One doi: 10.1371/journal.pone.0203143 – year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0365 – volume: 49 start-page: 64 issue: 1 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0130 article-title: Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs publication-title: Vet Res doi: 10.1186/s13567-018-0560-8 – volume: 21 start-page: 2040 issue: 11 year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0185 article-title: Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands publication-title: Emerg Infect Dis doi: 10.3201/eid2111.140780 – volume: 12 start-page: 708 issue: 4 year: 1990 ident: 10.1016/j.ijid.2019.10.005_bib0270 article-title: Life-threatening Haemophilus influenzae infections in Scandinavia: a five-country analysis of the incidence and the main clinical and bacteriologic characteristics publication-title: Rev Infect Dis doi: 10.1093/clinids/12.4.708 – volume: 354 start-page: 1455 issue: 14 year: 2006 ident: 10.1016/j.ijid.2019.10.005_bib0195 article-title: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae publication-title: N Engl J Med doi: 10.1056/NEJMoa051642 – volume: 50 start-page: 110 issue: 2 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0380 article-title: Understanding modern-day vaccines: what you need to know publication-title: Ann Med doi: 10.1080/07853890.2017.1407035 – volume: 115 start-page: 12887 issue: 51 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0015 article-title: Technologies to address antimicrobial resistance publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1717160115 – year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0395 – volume: 13 start-page: 744 issue: 4 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0050 article-title: Immune persistence after pertussis vaccination publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2016.1259780 – volume: 23 start-page: 1012 issue: 6 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0005 article-title: Penicillin resistance of nonvaccine type pneumococcus before and after PCV13 introduction, United States publication-title: Emerg Infect Dis doi: 10.3201/eid2306.161331 – volume: 50 start-page: 49 issue: Suppl. S1 year: 2002 ident: 10.1016/j.ijid.2019.10.005_bib0125 article-title: The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkf810 – volume: 34 start-page: 260 issue: 3 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0205 article-title: Effects of antibiotics on gut microbiota publication-title: Dig Dis doi: 10.1159/000443360 – volume: 56 start-page: 4965 issue: 9 year: 2012 ident: 10.1016/j.ijid.2019.10.005_bib0095 article-title: Serotype and clonal evolution of penicillin-nonsusceptible invasive Streptococcus pneumoniae in the 7-valent pneumococcal conjugate vaccine era in Italy publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00830-12 – volume: 5 start-page: e1176 issue: 12 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0100 article-title: Vaccination to reduce antimicrobial resistance publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30364-9 – volume: 34 start-page: 2075 issue: 11 year: 1990 ident: 10.1016/j.ijid.2019.10.005_bib0160 article-title: Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.34.11.2075 – year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0415 – volume: 48 start-page: 2206 issue: 6 year: 2004 ident: 10.1016/j.ijid.2019.10.005_bib0325 article-title: Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.6.2206-2213.2004 – volume: 142 start-page: 64 issue: 1 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0230 article-title: Vaccination-induced herd immunity: successes and challenges publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2018.05.007 – volume: 121 start-page: 253 issue: 2 year: 2008 ident: 10.1016/j.ijid.2019.10.005_bib0425 article-title: Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004 publication-title: Pediatrics doi: 10.1542/peds.2007-0619 – year: 2013 ident: 10.1016/j.ijid.2019.10.005_bib0245 – volume: 116 start-page: 18655 issue: 37 year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0065 article-title: A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1907833116 – volume: 201 start-page: 32 issue: 1 year: 2010 ident: 10.1016/j.ijid.2019.10.005_bib0275 article-title: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine publication-title: J Infect Dis doi: 10.1086/648593 – volume: 24 start-page: 10 issue: 1 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0145 article-title: The role of vaccines in preventing bacterial antimicrobial resistance publication-title: Nat Med doi: 10.1038/nm.4465 – volume: 7 issue: 3 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0220 article-title: How can vaccines contribute to solving the antimicrobial resistance problem? publication-title: mBio doi: 10.1128/mBio.00428-16 – volume: 185 start-page: 1528 issue: 6 year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0165 article-title: The role of viral, host, and secondary bacterial factors in influenza pathogenesis publication-title: Am J Pathol doi: 10.1016/j.ajpath.2014.08.030 – volume: 34 start-page: 227 issue: 3 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0360 article-title: Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European Vaccine Economics Community publication-title: PharmacoEcon doi: 10.1007/s40273-015-0335-2 – year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0260 – volume: 19 start-page: 56 issue: 1 year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0035 article-title: Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30605-4 – volume: 369 issue: 1645 year: 2014 ident: 10.1016/j.ijid.2019.10.005_bib0105 article-title: The contribution of vaccination to global health: past, present and future publication-title: Philos Trans R Soc Lond B Biol Sci doi: 10.1098/rstb.2013.0433 – volume: 7 issue: 12 year: 2012 ident: 10.1016/j.ijid.2019.10.005_bib0320 article-title: Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains publication-title: PLoS One doi: 10.1371/journal.pone.0050688 – year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0335 – year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0410 – volume: 6 start-page: 1543 year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0075 article-title: Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances publication-title: Front Microbiol – volume: 358 start-page: j3415 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0310 article-title: New chapter in tackling antimicrobial resistance in Thailand publication-title: BMJ doi: 10.1136/bmj.j2423 – volume: 49 start-page: 750 issue: 5 year: 2009 ident: 10.1016/j.ijid.2019.10.005_bib0190 article-title: The effect of universal influenza immunization on antibiotic prescriptions: an ecological study publication-title: Clin Infect Dis doi: 10.1086/605087 – ident: 10.1016/j.ijid.2019.10.005_bib0135 – volume: 7 issue: 10 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0240 article-title: Antibiotic-resistant salmonella in the food supply and the potential role of antibiotic alternatives for control publication-title: Foods (Basel, Switzerland) – volume: 40 start-page: 277 issue: 4 year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0375 article-title: The antibiotic resistance crisis: part 1: causes and threats publication-title: Pharm Ther – volume: 133 start-page: 493 issue: 3 year: 2005 ident: 10.1016/j.ijid.2019.10.005_bib0330 article-title: Penicillin-resistant pneumococcal meningitis: high antibiotic exposure impedes new vaccine protection publication-title: Epidemiol Infect doi: 10.1017/S0950268804003565 – volume: 4 start-page: 229 issue: 2 year: 1998 ident: 10.1016/j.ijid.2019.10.005_bib0020 article-title: Haemophilus influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease publication-title: Emerg Infect Dis doi: 10.3201/eid0402.980210 – year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0390 – year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0045 – volume: 12 issue: 1 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0290 article-title: Barriers of influenza vaccination intention and behavior — a systematic review of influenza vaccine hesitancy, 2005–2016 publication-title: PLoS One doi: 10.1371/journal.pone.0170550 – volume: 375 start-page: 2293 issue: 23 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0300 article-title: Real-world evidence — what is it and what can it tell us? publication-title: N Engl J Med doi: 10.1056/NEJMsb1609216 – volume: 49 start-page: 2561 issue: 6 year: 2005 ident: 10.1016/j.ijid.2019.10.005_bib0120 article-title: Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.6.2561-2564.2005 – volume: 552 start-page: 165 issue: 7684 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0285 article-title: Deploy vaccines to fight superbugs publication-title: Nature doi: 10.1038/d41586-017-08323-0 – volume: 70 start-page: 1087 issue: 12 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0305 article-title: Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps publication-title: J Antibiot doi: 10.1038/ja.2017.124 – year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0405 – year: 2013 ident: 10.1016/j.ijid.2019.10.005_bib0040 – volume: 10 start-page: S122 issue: 12 Suppl year: 2004 ident: 10.1016/j.ijid.2019.10.005_bib0215 article-title: Antibacterial resistance worldwide: causes, challenges and responses publication-title: Nat Med doi: 10.1038/nm1145 – volume: 205 start-page: 401 issue: 3 year: 2012 ident: 10.1016/j.ijid.2019.10.005_bib0110 article-title: Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines publication-title: J Infect Dis doi: 10.1093/infdis/jir755 – volume: 25 start-page: 1213 issue: 10 year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0030 article-title: Impact of vaccination on antibiotic usage: a systematic review and meta-analysis publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2019.06.030 – year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0090 – volume: 9 start-page: 1068 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0315 article-title: Changing priorities in vaccinology: antibiotic resistance moving to the top publication-title: Front Immunol doi: 10.3389/fimmu.2018.01068 – year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0400 – volume: 115 start-page: 12911 issue: 51 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0295 article-title: Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1717161115 – year: 2008 ident: 10.1016/j.ijid.2019.10.005_bib0385 – volume: 37 start-page: e145 issue: 6 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0225 article-title: Pertussis outbreak in a primary school in China: infection and transmission of the macrolide-resistant Bordetella pertussis publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000001814 – volume: 370 issue: 1670 year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0235 article-title: Carriage burden, multiple colonization and antibiotic pressure promote emergence of resistant vaccine escape pneumococci publication-title: Philos Trans R Soc Lond B Biol Sci doi: 10.1098/rstb.2014.0342 – volume: 11 issue: 6 year: 2014 ident: 10.1016/j.ijid.2019.10.005_bib0350 article-title: Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial publication-title: PLoS Med doi: 10.1371/journal.pmed.1001657 – volume: 28 start-page: 3650 issue: 21 year: 2010 ident: 10.1016/j.ijid.2019.10.005_bib0370 article-title: A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2010.03.030 – volume: 62 start-page: 1119 issue: 9 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0345 article-title: Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine publication-title: Clin Infect Dis doi: 10.1093/cid/ciw067 – year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0280 – volume: 13 issue: 3 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0210 article-title: Antibiotic resistance in India: drivers and opportunities for action publication-title: PLoS Med doi: 10.1371/journal.pmed.1001974 – volume: 38 start-page: 370 issue: 4 year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0080 article-title: Bordetella pertussis infection in infants and young children in Shanghai, China, 2016-2017: clinical features, genotype variations of antigenic genes and macrolides resistance publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000002160 – volume: 284 start-page: 1 issue: 1851 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0175 article-title: Why does drug resistance readily evolve but vaccine resistance does not? publication-title: Proc Biol Sci – volume: 115 start-page: 12868 issue: 51 year: 2018 ident: 10.1016/j.ijid.2019.10.005_bib0025 article-title: Antimicrobial resistance and the role of vaccines publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1717157115 – volume: 22 start-page: 10 issue: 1 year: 2003 ident: 10.1016/j.ijid.2019.10.005_bib0070 article-title: Impact of the pneumococcal conjugate vaccine on otitis media publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-200301000-00006 – volume: 342 start-page: 225 issue: 4 year: 2000 ident: 10.1016/j.ijid.2019.10.005_bib0255 article-title: The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children publication-title: N Engl J Med doi: 10.1056/NEJM200001273420401 – year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0355 – volume: 50 start-page: 202 issue: 2 year: 2010 ident: 10.1016/j.ijid.2019.10.005_bib0150 article-title: Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods publication-title: Clin Infect Dis doi: 10.1086/648678 – volume: 10 start-page: 394 issue: 5 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0180 article-title: The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12398 – volume: 19 start-page: e26 issue: 1 year: 2019 ident: 10.1016/j.ijid.2019.10.005_bib0010 article-title: Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30350-5 – volume: 55 start-page: 724 issue: 3 year: 2017 ident: 10.1016/j.ijid.2019.10.005_bib0265 article-title: Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States publication-title: J Clin Microbiol doi: 10.1128/JCM.01778-16 – volume: 10 issue: 3 year: 2015 ident: 10.1016/j.ijid.2019.10.005_bib0155 article-title: Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children—a population-based study publication-title: PLoS One doi: 10.1371/journal.pone.0120290 – volume: 12 start-page: 277 issue: 2 year: 2016 ident: 10.1016/j.ijid.2019.10.005_bib0055 article-title: The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014 publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2015.1116654 – volume: 16 start-page: 133 issue: 2 year: 2010 ident: 10.1016/j.ijid.2019.10.005_bib0170 article-title: Après 20 ans de vaccination efficace, que reste-t-il des infections à Haemophilus influenzae? publication-title: Med Ther
SSID	ssj0004668
Score	2.5788317
SecondaryResourceType	review_article
Snippet	[Display omitted] •The inappropriate use and overuse of antibiotics accelerates antimicrobial resistance (AMR).•New antibiotic development has declined sharply... Antibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has become a prolific global issue, due to... Drivers of antimicrobial resistance: Antibiotic use drives the development and spread of resistant bacterial infections. Antimicrobial resistance (AMR) has...
SourceID	doaj proquest pubmed crossref elsevier
SourceType	Open Website Aggregation Database Index Database Enrichment Source Publisher
StartPage	188
SubjectTerms	Animals Anti-Bacterial Agents - pharmacology Antibiotic Antimicrobial resistance Bacteria - drug effects Bacteria - genetics Bacteria - immunology Bacterial Infections - drug therapy Bacterial Infections - microbiology Bacterial Vaccines - genetics Bacterial Vaccines - immunology Drug Resistance, Bacterial Humans Inappropriate Prescribing Vaccine
Title	Impact of vaccines on antimicrobial resistance
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1201971219303972 https://dx.doi.org/10.1016/j.ijid.2019.10.005 https://www.ncbi.nlm.nih.gov/pubmed/31622674 https://www.proquest.com/docview/2307130844 https://doaj.org/article/f34071fda3084dad896547e5368f1656
Volume	90
WOSCitedRecordID	wos000502803300029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1878-3511 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004668 issn: 1201-9712 databaseCode: DOA dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NSx0xEB9aKUUoxWqtr1pZoTdZu9kku5ujLRWFVnqw8m4hmw9YsfvE9_Tv70yyu-iheuk1JNnsZCbzm2Q-AD5Lp1D-nMvRnra5aKTIFRd1XilWuqoITYg1li5_1OfnzXyufj0o9UU-YSk9cCLcl8DJ5AjO8KIRzrhGUblcL3mF0yAYodMXUc9oTE0RkSkIDtVbrmpWDuEyybOru-ooRyhTR9GvSz5SSTFz_yPN9C_kGTXQyQa8HaBjdpyW_A5e-H4TXv8cHsc34U26gstSZNEWHJ3FCMhsEbJ7Y6nPMlv0GZKy-9PF_Es4G1rbhCBx69_D75PvF99O86E8Qm5lw1d5VXCDdjGXIfhGCYPnhah4EVobbGlR0FwtnbBWWsMNc6X3lVe1cwaFGIFJ4Nuw1i96vwNZ0SJSaGvDCtcK1pqWt65EYreIZh1zfAZspJC2Q-5wKmFxrUcnsStNVNVEVWpDqs7gcBpzkzJnPNn7KxF-6klZr2MD8oIeeEE_xwsz4OO26TGwFI9CnKh78tNyGjXAjgQnnh13MHKGRpmkhxbT-8XdUpNzPaM1ihl8SCwz_RhnFSLeWnz8Hz-8C-sl2f_xSmgP1la3d_4TvLL3q255uw8v63mzHwXjLxPnC2I
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+vaccines+on+antimicrobial+resistance&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Buchy%2C+Philippe&rft.au=Ascioglu%2C+Sibel&rft.au=Buisson%2C+Yves&rft.au=Datta%2C+Sanjoy&rft.date=2020-01-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.volume=90&rft.spage=188&rft.epage=196&rft_id=info:doi/10.1016%2Fj.ijid.2019.10.005&rft.externalDocID=S1201971219303972
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon